Local budesonide therapy in the management of persistent hyposmia in suspected non-severe COVID-19 patients: Results of a randomized controlled trial

被引：2

作者：

Hautefort, Charlotte ^{[1
]}

Corre, Alain ^{[2
]}

Poillon, Guillaume ^{[3
]}

Jourdaine, Clement ^{[1
]}

Housset, Juliette ^{[1
]}

Eliezer, Michael ^{[3
,4
]}

Verillaud, Benjamin ^{[1
]}

Slama, Dorsaf ^{[5
]}

Ayache, Denis ^{[2
]}

Herman, Philippe ^{[1
]}

Yavchitz, Amelie ^{[6
]}

Guillaume, Jessica

Herve, Camille ^{[2
]}

El Bakkouri, Wissame ^{[2
]}

Salmon, Dominique ^{[5
]}

Daval, Mary ^{[2
]}

机构：

[1] Univ Paris, Hop Lariboisiere, ENT Dept, APHP, Paris, France

[2] Hop Fdn Adolphe Rothschild, ENT Dept, Paris, France

[3] Hop Fdn Adolphe Rothschild, Imaging Dept, Paris, France

[4] Univ Paris, Hop Lariboisiere, Neuroradiol Dept, APHP, Paris, France

[5] Univ Paris, Hop Hotel Dieu, Dept Infect Dis, APHP, Paris, France

[6] Hop Fdn Adolphe Rothschild, Clin Res Dept, Paris, France

来源：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2023年 / 136卷

关键词：

Budesonide; COVID-19; Persistent hyposmia; Olfactory rehabilitation; ODORATEST;

D O I：

10.1016/j.ijid.2023.08.022

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: Consequences of COVID-19 on olfactory functions remained unclear during the pandemic. We assessed the efficacy of local budesonide in addition to olfactory rehabilitation when managing non -severe COVID-19 patients with persistent hyposmia.Methods: A multicentric, randomized, superiority trial was conducted (ClinicalTrials.gov NCT04361474). The experimental group (EG) received budesonide and physiological saline nasal irrigations administered via three syringes of 20 ml in each nasal cavity in the morning and evening for 30 days. The control group (CG) received a similar protocol without budesonide. Patients were included if they were > 18 years old, with a SARS-CoV-2 infection and presenting an isolated hyposmia persisting 30 days after symptom onset. The primary endpoint was the percentage of patients with improvement of more than two points on the ODORATEST score after 30 days of treatment.Results: In total, 123 patients were included and randomized (EG: 62 vs CG: 61). Two patients from the EG met the primary endpoint with no statistical difference between the two groups ( P = 0.5).Conclusion: To our knowledge, this is the first study evaluating local budesonide for COVID-19 related hyposmia treatment even though previous trials were performed with other local corticosteroids. Local budesonide efficacy was not demonstrated for persistent hyposmia related to COVID-19.

引用

页码：70 / 76

页数：7

共 35 条

[1] Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial [J].